 "Pharma exporters hope for a barter-deal with African nations to beat currency blues")
Strides Shasun has rallied 7% to Rs 1,205 on the BSE in intra-day trade after the company announced successful completion of the United States Food and Drug Administration (USFDA) inspection of its oral dosage facility in Bangalore with 'Zero 483s'.
“The oral dosage facility in Bangalore manufactures oral dosage forms including tablets, capsules, ointments and liquids. The manufacturing plant supports important current and future submissions for the US market”, Strides Shasun said.
The audit was carried out related to a product filed from the new semi solids block from where the company has made a series of filings. With the recently closed Establishment Inspection Report (EIR), the entire facility is now USFDA compliant, it added.
At 10:20 AM, the stock was up 5% at Rs 1,185 on the BSE. The trading volumes on the counter more than doubled with a combined 529,922 shares changed hands on the BSE and NSE so far.
“The oral dosage facility in Bangalore manufactures oral dosage forms including tablets, capsules, ointments and liquids. The manufacturing plant supports important current and future submissions for the US market”, Strides Shasun said.
The audit was carried out related to a product filed from the new semi solids block from where the company has made a series of filings. With the recently closed Establishment Inspection Report (EIR), the entire facility is now USFDA compliant, it added.
At 10:20 AM, the stock was up 5% at Rs 1,185 on the BSE. The trading volumes on the counter more than doubled with a combined 529,922 shares changed hands on the BSE and NSE so far.
